A Preview of coming attractions

As Momma Kliff used to say the more things change the more they remain the same. We couldn’t help but feel this way while listening to Lilly’s (NYSE: LLY) earnings call this morning. Once again, the diabetes drug space is the domain of Lilly and Novo Nordisk (NYSE: NVO). We were also encouraged by some of the comments made by the company related to the coming of a biosimilar short-acting insulin.

Let’s cover that last point first as the company noted they will NOT sue Sanofi (NYSE: SNY) over their short-acting biosimilar. It . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

This entry was posted in Email Alerts. Bookmark the permalink.